Wouter van Geffen

13PUBLICATIONS

32CO-AUTHORS

Molecular targetsPredictive and prognostic markersCardiology (incl. cardiovascular diseases)Cancer therapy (excl. chemotherapy and radiation therapy)Solid tumours

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (13)

Sort by Publication Date:

|Jun 26, 2026

Age-Stratified Long-Term Outcomes of Immune Checkpoint Inhibitors for Stage IV Melanoma and NSCLC in The Netherlands: A Population-Based Study.

|Jun 03, 2026

Externally Tested AI Models for Malignancy Classification of Lung Nodules at CT: A Systematic Review and Meta-Analysis.

|Feb 20, 2026

LAMA and ICS discontinuation in COPD: run-in to an exacerbation?

Bram van den Borst, Wouter Heero van Geffen

|Feb 17, 2026

KRAS G12C inhibitors versus chemotherapy in second line and beyond in adults with advanced or metastatic non-small cell lung cancer (NSCLC) harbouring the KRAS G12C mutation.

Anneloes Noordhof, Oke Dimas Asmara, Kim de Jong

|Apr 01, 2025

Anti-inflammatory effects of tiotropium in COPD: a randomised double-blind trial.

Lisa H van Smoorenburg, Tatiana Karp, Benedikt Ditz

|Oct 03, 2024

Stage III NSCLC treatment options: too many choices.

Oke Dimas Asmara, Georgia Hardavella, Sara Ramella

Pageof 3

Frequent Collaborators

Mina Gaga

Helmut Prosch

Rolof Gijtenbeek

Anna Kerpel-Fronius

David R Baldwin

Marie-Pierre Revel

Herbert Decaluwe

Jan van Meerbeeck

Joanna Chorostowska-Wynimko

2 joint publications

Oke Dimas Asmara

Frequent Collaborators

Mina Gaga

Helmut Prosch

Rolof Gijtenbeek

Anna Kerpel-Fronius